跳至主要内容
临床试验/JPRN-jRCT2080222579
JPRN-jRCT2080222579未知1 期

Phase I Clinical Study of GDC-0032 in Patients With Advanced Solid Cancers or GDC-0032 in Combination With Fulvestrant in Patients With Hormone Receptor-positive Locally Advanced or Metastatic Breast Cancer

Chugai Pharmaceutical Co., Ltd.0 个研究点目标入组 30 人开始时间: 2014年8月11日最近更新:
适应症

试验速览

阶段
1 期
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Histologically or cytologically documented solid cancer.
  • Advanced or recurrent cancer for which standard treatment is ineffective or for which there is no established standard treatment.
  • Females who are histologically or cytologically documented breast cancer.
  • Hormone receptor positive locally advanced or metastatic breast cancer for which endocrine therapy is indicated.

排除标准

  • Diabetes mellitus requiring drug treatment.
  • Central nervous system metastases that are symptomatic or require treatment.
  • Grade 3 or more adverse event during prior treatment with P13K inhibitor, or at high risk if again treated with P13K inhibitor.

研究者

相似试验